Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Bone Marrow Transplantation

• Publication date

  1991-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 2070147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A PHASE I‐II STUDY EVALUATING THE MURINE ANTI‐IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE

  1990cited by this paper
• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  1990cited by this paper
• Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

  1990cited by this paper
• Alloantigen-specific T suppressor-inducer and T suppressor-effector cells can be activated despite blocking the IL-2 receptor.

  1990cited by this paper
• Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.

  1989cited by this paper
• Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.

  1989cited by this paper
• PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL IN MURINE RECIPIENTS TREATED WITH A DIPHTHERIA TOXIN RELATED INTERLEUKIN‐2 FUSION PROTEIN

  1989cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper
• Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay.

  1989cited by this paper
• Indications for marrow transplantation in chronic myelogenous leukemia.

  1989cited by this paper
• Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

  1989cited by this paper
• IL-4 bypasses the immune suppressive effect of cyclosporin A during the in vitro induction of murine cytotoxic T lymphocytes.

  1988cited by this paper
• Treatment of acute graft-versus-host disease with monoclonal antibody to IL-2 receptor.

  1988cited by this paper
• Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor- mediated action of a diphtheria toxin-related interleukin 2 fusion protein

  1988cited by this paper
• The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.

  1988cited by this paper
• The interleukin 2 receptor.

  1988cited by this paper
• The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.

  1987cited by this paper
• Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

  1987cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

  1986cited by this paper
• Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation.

  1986cited by this paper
• Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.

  1986cited by this paper
• Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody.

  1986cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

  1986cited by this paper
• Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

  1986cited by this paper
• Prolongation of murine skin allograft survival by immunologic manipulation with anti-interleukin 2 receptor antibody.

  1986cited by this paper
• The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

  1986cited by this paper
• Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice

  1985cited by this paper
• Marrow transplantation from related donors other than HLA-identical siblings.

  1985cited by this paper
• THE EFFECT OF ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY ON ALLOGRAFT REJECTION

  1985cited by this paper
• Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia.

  1983cited by this paper
• Transient expression of interleukin 2 receptors. Consequences for T cell growth

  1983cited by this paper
• A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

  1982cited by this paper
• T cell growth factor receptors. Quantitation, specificity, and biological relevance

  1981cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

  1981cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper
• Bone-marrow transplantation (second of two parts).

  1975cited by this paper
• Bone-marrow transplantation (first of two parts).

  1975cited by this paper

• Graft-Versus-Host Disease

  2016cites this paper
• Zytokine und Zytokinantagonisten

  2014cites this paper
• Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.

  2012cites this paper
• Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases

  2012cites this paper
• [Role of monoclonal antibodies in the treatment of acute graft versus host disease].

  2007cites this paper
• Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.

  2006cites this paper
• Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.

  2005cites this paper
• Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies

  2005cites this paper
• Graft-versus-host disease: how to translate new insights into new therapeutic strategies.

  2004cites this paper
• Haploidentical Stem Cell Transplantation

  2004cites this paper
• Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.

  2004cites this paper
• Serum levels of cytokines correlate to donor chimerism and acute graft‐vs.‐host disease after haematopoietic stem cell transplantation

  2003cites this paper
• Adoptive Cellular Therapy: A Therapeutic Reality?

  2002cites this paper
• The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

  2002cites this paper
• New developments in the prophylaxis and treatment of graft versus host disease

  2001cites this paper
• Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins.

  2001cites this paper
• Management of Graft-Versus-Host Disease in Paediatric Bone Marrow Transplant Recipients

  2000cites this paper
• Pathophysiology and treatment of graft-versus-host disease.

  1999cites this paper
• IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells

  1998cites this paper
• Graft-versus-Host Disease

  1998cites this paper
• Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease.

  1998cites this paper
• Cytokine Dysregulation in Acute Graft-versus-Host Disease.

  1997cites this paper
• The role of cytokines in acute graft-versus-host disease.

  1997cites this paper
• Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease.

  1997cites this paper
• Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.

  1997cites this paper
• UVB-irradiation of human bone marrow: potential for donor specific tolerance.

  1996cites this paper
• THE TISSUE EXPRESSION OF CYTOKINES IN HUMAN ACUTE CUTANEOUS GRAFT‐VERSUS‐HOST DISEASE

  1995cites this paper
• Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis.

  1995cites this paper
• Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.

  1995cites this paper
• The Clinical and Experimental Use of Monoclonal Antibodies to the IL-2 Receptor

  1995cites this paper
• Effects of ultraviolet-B irradiation on human LAK and NK cytotoxic activity.

  1995cites this paper
• INTERLEUKIN‐2 FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION

  1994cites this paper
• Donor B cell lymphoma of the brain after allogeneic bone marrow transplantation for acute myeloid leukemia.

  1994cites this paper
• THE USE OF MONOCLONAL ANTIBODIES IN ALLOGENEIC BONE MARROW TRANSPLANTATION

  1993cites this paper
• Current thoughts on the pathogenesis of graft versus host disease.

  1993cites this paper
• Use of an anti-interleukine 2 receptor monoclonal antibody for GvHD prophylaxis in unrelated bone marrow transplantation. GEGMO Group.

  1993cites this paper
• Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC.

  1993cites this paper
• Prevention and Treatment of Acute Graft‐vs.-Host Disease

  1993cites this paper
• Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT.

  1993cites this paper
• Immunoregulation by cytokines.

  1993cites this paper
• Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.

  1992cites this paper
• Interleukin‐2 Receptor‐Directed Immunosuppressive Therapies: Antibody‐ or Cytokine‐Based Targeting Molecules

  1992cites this paper
• Chapter 19. Monoclonal Antibodies in Therapy

  1992cites this paper
• Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy.

  1992cites this paper
• Leaders Current thoughts on the pathogenesis of graft versus host disease

  year unknowncites this paper